Yantai Dongcheng reports FY24 results, outlines growth strategy

** Yantai Dongcheng Biochemicals (SZSE:002675) reported FY24 financials with revenue declining 12.42% year-over-year to RMB 2.87 billion and net profit attributable to shareholders dropping 12.35% to RMB 183.83 million. The company has approved a plan to allocate RMB 24.74 million in cash dividends. As part of its strategy, Yantai Dongcheng is developing its business by establishing radiopharmaceutical production networks, and the company expects to soon gain access to key isotopes through strategic partnerships, bolstering its radiopharmaceutical capabilities. R&D investment increased to RMB 291.91 million. The company outlined goals to become a leading pharmaceutical company through quality products, diversified business segments, and improved management.